Electronic Resource
A multicenter, phase II trial of preoperative gemcitabine and nabpaclitaxel for resectable pancreas cancer: The AGITG GAP study.
| العنوان: | A multicenter, phase II trial of preoperative gemcitabine and nabpaclitaxel for resectable pancreas cancer: The AGITG GAP study. |
|---|---|
| المؤلفون: | Gebski V., Harris M., Aghmesheh M., Joubert W.L., Simes J., Goldstein D., Barbour A., O'Rourke N., Chandrasegaram M.D., Chua Y.J., Kench J., Samra J.S., Pavlakis N., Haghighi K.S., Yip S., Fawcett J., Donoghoe M., Walker K., Burge M.E., Gananadha S. |
| بيانات النشر: | American Society of Clinical Oncology 2015-09-22 |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | Background: Recent pancreatic cancer (PC) series show 41% (95%CI 40-43%) of patients (pts) achieve an R0 resection (margin clearance 1mm). In neoadjuvant chemotherapy trials for resectable PC, only 5489% undergo pancreatic resection with R0 rates of 7480%. Nabpaclitaxel( nabpacli) and gemcitabine(GEM) chemotherapy(CX) is an active regimen in metastatic disease. We aimed to determine feasibility and R0 resection rate of 85% with perioperative nabpacli and GEM for resectable PC. Method(s): Pts with operable PC received 2 cycles of neoadjuvant nabpacli 125mg/m2 followed by GEM 1000mg/m2CX on days(D) 1, 8 and 15(28D cycle) followed by resection and then postoperative CX(4 cycles). Result(s): Fortyone pts were enrolled (201214). Median age = 65 (range 4379), 41% male. Thirtysix (88%) pts underwent surgery, while five (12%) did not (2 disease progression, 2 refused surgery, 1 cholangitis). Only 4/36 (10%) had grade septic events, no grade pancreatic leak, and no treatment related deaths. Thirty pts had pancreatic resection (73%; 29 had evaluable cancer and 15/29 (52%) had grade 02 tumour regression; one did not have cancer on central pathology review). Six (15%) pts had unresectable disease at surgery. Preoperative nabpacli and GEM produced an R0 rate of 52% (15/29; 95%CI 34-69%) with a minimum 1mm margin and an R0 rate of 86% (25/29; 95%CI 68-96%) with a 0mm margin. 39/41 (95%) completed planned induction CX (although dose modifications/omission were required mostly omission of D15). Postoperatively, eighteen pts (18/30, 60%) commenced CX, with 14/18 (78%) completing all 4 cycles of planned CX; whilst four pts commenced chemoradiation, but 2 withdrew due to disease progression. Conclusion(s): Preoperative nabpacli and GEM was delivered safely and achieved an R0 resection rate clinically significantly higher than the mean of surgical series using similar pathology criteria. Our preoperative regimen was delivered to 95% of patients, but in contrast postoperative CX was les |
| مصطلحات الفهرس: | phase 2 clinical trial, surgery, patient, neoplasm, disease course, pathology, tumor regression, death, cholangitis, metastasis, chemotherapy, adjuvant chemotherapy, chemoradiotherapy, male, gemcitabine, society, American, oncology, human, pancreas cancer, Conference Abstract |
| URL: | Click here for full text options LibKey Link |
| الاتاحة: | Open access content. Open access content Copyright 2015 Elsevier B.V., All rights reserved. |
| Other Numbers: | AUSHL oai:repository.monashhealth.org:1/41363 Journal of Clinical Oncology. Conference: 2015 Annual Meeting of the American Society of Clinical Oncology, ASCO. Chicago, IL United States. Conference Publication: (var.pagings). 33 (15 SUPPL. 1) (no pagination), 2015. Date of Publication: 20 May 2015. 0732-183X https://repository.monashhealth.org/monashhealthjspui/handle/1/41363 Pathology Oncology 72011880 (Barbour, O'Rourke, Chandrasegaram, Chua, Kench, Samra, Pavlakis, Haghighi, Yip, Fawcett, Donoghoe, Walker, Burge, Gananadha, Harris, Aghmesheh, Joubert, Gebski, Simes, Goldstein) University of Queensland, Brisbane, Australia; Royal Brisbane and Women's Hospital Herston, Australia; NHMRC Clinical Trials Centre, Sydney, Australia; The Canberra Hospital, Woden, Australia; Department of Tissue Pathology and Diagnostic Oncology Royal Prince Alfred Hospital, Sydney, Australia; Department of Surgery, Royal North Shore Hospital, Sydney, Australia; Department of Medical Oncology, Royal North Shore Hospital, The University of Sydney, Sydney, Australia; University of South Wales, Prince of Wales Hospital, Sydney, Australia; Sydney Catalyst Translational Cancer Research Centre Sydney, Australia; Queensland Liver Transplant Service, Brisbane, Australia; ANU Medical School, The Canberra Hospital, Garran, Australia; Monash Medical Centre, Melbourne Australia; Illawarra Cancer Care Centre, Wollongong, Australia; Princess Alexandra Hospital, Brisbane, Australia; National Health and Medical Research Council Clinical Trials Centre, Sydney, Australia; Prince of Wales Hospital, University of New South Wales Cancer Survivors Centre, Sydney, Australia (Barbour, O'Rourke, Chandrasegaram, Chua, Kench, Samra, Pavlakis, Haghighi, Yip, Fawcett, Donoghoe, Walker, Burge, Gananadha, Harris, Aghmesheh, Joubert, Gebski, Simes, Goldstein) University of Queensland, Brisbane, Australia; Royal Brisbane and Women's Hospital Herston, Australia; NHMRC Clinical Trials Centre, Sydney, Australia; The Canberra Hospital, Woden, Australia; Department of Tissue Pathology and Diagnostic Oncology Royal Prince Alfred Hospital, Sydney, Australia; Department of Surgery, Royal North Shore Hospital, Sydney, Australia; Department of Medical Oncology, Royal North Shore Hospital, The University of Sydney, Sydney, Australia; University of South Wales, Prince of Wales Hospital, Sydney, Australia; Sydney Catalyst Translational Cancer Research Centre Sydney, Australia; Queensland Liver Transplant Service, Brisbane, Australia; ANU Medical School, The Canberra Hospital, Garran, Australia; Monash Medical Centre, Melbourne Australia; Illawarra Cancer Care Centre, Wollongong, Australia; Princess Alexandra Hospital, Brisbane, Australia; National Health and Medical Research Council Clinical Trials Centre, Sydney, Australia; Prince of Wales Hospital, University of New South Wales Cancer Survivors Centre, Sydney, Australia 1305129719 |
| المصدر المساهم: | MONASH HEALTH LIBRS From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.on1305129719 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |